Diagnostic potential of one-step nucleic acid amplification assay in patients with head and neck squamous cell carcinoma based on CK19 expression in a primary lesion by 鈴木, 政博 & Suzuki, Masahiro
Fukushima Medical University
福島県立医科大学 学術機関リポジトリ
This document is downloaded at: 2020-01-06T12:33:49Z
Title
Diagnostic potential of one-step nucleic acid amplification
assay in patients with head and neck squamous cell carcinoma
based on CK19 expression in a primary lesion( 全文 )
Author(s)鈴木, 政博
Citation
Issue Date2015-09-28
URL http://ir.fmu.ac.jp/dspace/handle/123456789/480
Rights
DOI
Text Versionnone
1 
 
Diagnostic potential of one-step nucleic acid amplification assay in patients with head and neck 
squamous cell carcinoma based on CK19 expression in a primary lesion 
 
 
Masahiro Suzuki1, MD, Takashi Matsuzuka1, MD, PhD, Yuko Hashimoto2, MD, PhD, 
Masakazu Ikeda1, MD, Satoshi Saijo1, MD, Koichi Omori1, MD, PhD    
 
 
 
1Department of Otolaryngology, Fukushima Medical University School of Medicine, 
Fukushima, Japan 
2Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, 
Fukushima, Japan 
 
 
 
 
 
Koichi Omori, MD, PhD  
Department of Otolaryngology, School of Medicine, Fukushima Medical University 
1 Hikarigaoka, Fukushima City, 960-1295, Japan 
Telephone: +81-24-547-1325 
Fax: +81-24-547-1325 
E-mail: omori@fmu.ac.jp  
 
Running title: Cervical metastases using OSNA assay 
 
Key Words: Molecular detection; lymph node metastases; OSNA assay; CK19; head and neck 
cancer 
 
 
2 
 
Abstract 
Background. This study aimed to investigate the effects of CK19 expression in the primary 
lesions of head and neck squamous cell carcinoma on the diagnosis of the cervical lymph node 
(CLN)  metastasis using the one-step nucleic acid amplification (OSNA) assay. 
Methods. Primary lesions and 54 CLNs were resected from 21 patients with head and neck 
squamous cell carcinoma between 2009 and 2011. Each CLN was tested by the OSNA assay, 
and the CK19 mRNA copy number obtained was compared to the corresponding 
histopathological results. 
Results. In the primary lesion CK19-positive group, the sensitivity and specificity of the OSNA 
assay against hematoxylin-eosin staining were 86% and 100%, respectively. The p value by 
Fisher’s exact test was less than 0.0001, indicating statistical significance. 
Conclusion. These results suggest that OSNA offers similar diagnostic potential to that of 
histopathological diagnosis of CLN biopsy in patients with a CK19-positive primary lesion.  
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Introduction 
Head and neck cancers generally begin in squamous cells, and over 500,000 new cases are 
diagnosed worldwide each year1. Approximately 60% of the cases are advanced stage III and IV 
cancer, which have a poor prognosis even with a multimodal therapeutic approach2. Metastasis 
to lymph nodes also often occurs in the early stages of cancer, and whether neck dissection 
should be performed as preventive treatment is controversial. Lymph node metastasis is an 
important prognostic factor in head and neck squamous cell carcinoma; thus, accurate 
diagnostic techniques are necessary.  
Sentinel lymph node biopsy, which enables highly accurate detection of regional lymph node 
metastasis3, has become a standard diagnostic and therapeutic modality for breast cancer. When 
a sentinel lymph node biopsy is negative, lymph node dissection can be avoided4. The principles 
of sentinel lymph node navigation surgery have been expanded to the treatment of other types of 
cancer including head and neck squamous cell carcinoma5-9.  
Lymph node metastasis, including metastasis to the sentinel lymph node, is diagnosed by 
examining the slices of sectioned specimens pathologically. Micrometastasis may not be 
detected unless the metastases appear in the sectioned slices. The development of a method to 
examine a whole lymph node specimen is therefore required. Such a method can be applied to 
intraoperative diagnosis if the presence or absence of metastasis is determined in a short time. 
CK19 is a typical epithelial cell marker expressed in human cancers but not in lymph nodes 
without metastasis. It is expressed in most, but not all, breast cancer cases10, suggesting there 
may be a CK19-negative subpopulation among patients with head and neck cancer. The origin 
of the cancer cell may be elucidated by examining the cytokeratin expression of cancer cells. 
Moreover, the examination of cytokeratin expression in lymph nodes has a diagnostic 
significance in metastasis. 
The one-step nucleic acid amplification (OSNA) assay for quantitatively detecting CK19 
mRNA is a molecular technique that rapidly detects lymph node metastasis and is already in use 
for intraoperative diagnosis of sentinel lymph node metastasis in breast cancer patients3,11-14. 
The validity of the OSNA assay for detecting lymph node metastasis has also been reported in 
patients with head and neck squamous cell carcinoma15,16. 
In head and neck squamous cell carcinoma, no report on the OSNA assay yet exists examining 
the detailed association of CK19 expression between a primary lesion and lymph nodes. 
This study intended to investigate the effects of CK19 expression in the primary lesions of head 
and neck squamous cell carcinoma on the diagnosis of the cervical lymph node (CLN) 
metastasis by molecular detection with the OSNA assay. 
In our current study, clinically non-metastatic cervical lymph nodes were examined using the 
OSNA assay in order to investigate feasibility of detecting lymph node metastasis. 
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Materials and Methods 
 
Patients 
Primary lesions and 54 CLNs resected from 21 patients with head and neck squamous cell 
carcinoma between 2009 and 2011 at Fukushima Medical University Hospital were examined. 
None of the 21 patients had a history of cancer, including squamous cell carcinoma, and had no 
evidence of distant metastasis. None received treatment prior to surgery.  
Characteristics of the 21 patients are summarized in Table 1. Median age was 67 years (range, 
38–80 years of age), and most patients were male. T stage was T2 or higher in almost all 
patients, and clinical N stage was N0 in 52% of patients.  
Examination prior to surgery revealed that enlargement and clinically evident metastasis were 
absent in all 54 CLNs. Two or three lymph nodes were randomly selected from those surgically 
resected in each patient during neck dissection. 
In the primary lesion of oral cavity and maxillary sinus, lymph nodes of cervical level I or II 
were selected. In the primary lesion of oropharynx, hypopharynx, and larynx, lymph nodes of 
cervical level II or III were selected. 
Intraoperative hematoxylin-eosin (HE) staining of frozen sections revealed metastasis in 9 of the 
54 CLNs. Results of HE staining of these frozen sections were in good agreement with those of 
HE staining of the corresponding permanent sections.  
This study was approved by the Institutional Ethics Review Board of Fukushima Medical 
University.  
 
Immunostaining in primary lesions 
Primary lesions excised during surgery were fixed in formalin and embedded in paraffin to 
prepare 5-µm slices. One slice was stained with HE, and the other slices were tested for CK19 
expression by immunostaining with the RCK108 monoclonal antibody (DAKO, Hamburg 
Germany).According to the immunohistochemical assessment using J-score17, when more than 
1% of tumor cells were immunostained in primary lesions, it was considered as CK19-positive 
by the pathologist in our hospital. 
 
Processing for HE staining, CK19 immunostaining, and OSNA assay of CLNs  
CLNs excised during surgery were divided into four equal portions (a-d, Fig. 1), two of which 
(b and d) were stored at −80°C until use in the OSNA assay. The other two portions (a and c) 
were processed in a similar manner to that used for primary lesions. Three pairs of 5-µm slices 
were prepared at each side adjacent to the corresponding portion. 
One slice of each pair was stained with HE, and the other was immunostained for CK19 
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detection in a similar manner to that used for the primary lesions. According to the 
immunohistochemical assessment using J-Score17, when more than 1% of tumor cells were 
immunostained in CLNs, it was considered as CK19-positive. The pathologists who performed 
the HE staining and immunostaining were blinded to the OSNA results. 
 
OSNA assay of CLNs 
The OSNA assay of the CLNs was performed according to a previously reported method3. 
Briefly, two frozen portions (b and d) were homogenized with 4 ml of a buffer (Lynorhag; 
Sysmex, Kobe, Japan) and centrifuged at 10,000 g at room temperature. Two microliters of the 
resulting supernatant was analyzed on an automated molecular detection system (RD-100i; 
Sysmex) using a ready-to-use Lynoamp Kit (Sysmex). Reverse transcription loop-mediated 
isothermal amplification (RT-LAMP), which completes gene amplification within 30 min, was 
used for detection of CK19 mRNA18.  
Amplicons were detected by real-time monitoring of turbidity caused by increasing levels of 
magnesium pyrophosphate (a byproduct of amplification). A total of six primers were used to 
perform highly specific reactions. Amplification of one specimen required less than 20 min. Full 
processing of three specimens was completed in approximately 30 min.  
Each assay tested a positive control containing 5,000 copies/µl of CK19 mRNA, which is 
considered to be equivalent to the amount of CK19 mRNA in 2 mm3 of breast cancer cells, and 
a negative control containing 0 copies/µl of CK19 mRNA for calibration. Results are expressed 
as concentrations of CK19 mRNA. Specimens of head and neck squamous cell cancer 
containing <1.31×102 copies/µl of CK19 mRNA were considered CK19 negative, and those 
containing ≥1.31×102 copies/µl of CK19 mRNA were considered CK19 positive15. Each CLN 
was tested by the OSNA assay, and the CK19 mRNA copy number obtained was compared to 
the corresponding histopathological results. 
 
Statistical analyses  
Sensitivity and specificity were calculated. Fisher’s exact test was used to test for statistical 
significance (p < 0.05). 
 
Results 
Results of all 21 primary lesions and 54 CLNs are summarized in Table 2. Immunostaining 
confirmed that 22 CLNs were from 9 patients with CK19-positive primary lesions (primary 
lesion CK19-positive group), whereas 32 were from 12 patients with CK19-negative primary 
lesions (primary lesion CK19-negative group). 
Of the 54 CLNs, CK19 was positive by immunostaining in 6 CLNs, whereas CK19 was 
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negative in 48 CLNs. In the primary lesion CK19-positive group, CK19 was positive by 
immunostaining in 6 CLNs (27%), whereas CK19 was negative in 16 CLNs (73%). In the 
primary lesion CK19-negative group, CK19 was determined to be negative by immunostaining 
in all 32 CLNs. 
The OSNA assay detected 8 positive CLNs (range, 1.31×102–9.5×105 copies/µl; mean 1.6×104 
copies/µl) and 46 negative CLNs (<1.31×102 copies/µl; some were under the detection limit).  
Six CLNs were CK19 positive by immunostaining and positive by the OSNA assay, 46 CLNs 
were CK19 negative by immunostaining and negative by the OSNA assay, and 2 CLNs were 
CK19 negative by immunostaining and positive by the OSNA assay.  
The sensitivity and specificity of the OSNA assay against CK19 immunostaining were 100% 
(95% CI: 68–100%) and 96% (95% CI: 92–96%), respectively (Fig.2). The p value by Fisher’s 
exact test was less than 0.0001, indicating statistical significance. 
In the primary lesion CK19-positive group, 7 CLNs (32%) contained metastatic cells diagnosed 
by HE staining, whereas 15 (68%) did not, and 6 CLNs (27%) were positive by the OSNA assay, 
whereas 16 (73%) were negative. One CLN containing metastatic cells diagnosed by HE 
staining was negative by CK19 immunostaining and the OSNA assay (mRNA level under the 
detection limit). The sensitivity and specificity of the OSNA assay against HE staining in this 
group were 86% (95% CI: 61–86%) and 100% (95% CI: 88–100%), respectively (Fig.3). The p 
value by Fisher’s exact test was less than 0.0001, indicating statistical significance. A 
representative case containing a primary lesion with HE staining and CK19 positive by 
immunostaining, and metastatic LN with HE staining and CK19 positive by immunostaining is 
demonstrated (Fig.4).  
In the primary lesion CK19-negative group, 2 CLNs (6%) contained metastatic cells diagnosed 
by HE staining, whereas 30 (94%) did not, and 2 CLNs (6%) were positive by the OSNA assay, 
whereas 30 (94%) were negative. In the 2 CLNs with metastatic cells diagnosed by HE staining, 
one was positive by the OSNA assay (1.31×102 copies/µl), whereas the other was negative (6 
copies/µl). Additionally, one of CLNs that did not contain metastatic cells diagnosed by HE 
staining was positive by the OSNA assay (1.4×103 copies/µl). In this group, the sensitivity and 
specificity of the OSNA assay against HE staining was 50% (95% CI: 10–86%) and 97% (95% 
CI: 94–99%), respectively (Fig.5). A representative case containing a primary lesion with HE 
staining and CK19 negative by immunostaining, and non-metastatic LN with HE staining and 
CK19 negative by immunostaining is demonstrated (Fig.6). 
 
Discussion  
Recently, sentinel lymph node biopsy, which enables highly accurate detection of regional 
lymph node metastasis3, has become a standard diagnostic and therapeutic modality for breast 
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cancer. When the sentinel lymph node biopsy is negative, lymph node dissection can be 
avoided4, thereby also reducing the risk for postoperative complications. The principles of 
sentinel lymph node navigation surgery, originally used in breast cancer treatment, have been 
expanded to the treatment of other types of cancer including head and neck squamous cell 
carcinoma5-9.  
Although detailed pathological examination of the sentinel lymph node offers highly accurate 
information on metastasis19, a considerable number of slices are required for high accuracy of 
pathological results20. Preparation of specimens is time consuming, and the examination of a 
high number of slices, especially during intraoperative examination, is a heavy burden on 
pathologists12. 
It is impossible to observe an entire lymph node by histopathological examination, and 
diagnostic results may differ depending on slices examined. However, molecular biological 
techniques can investigate global events in the lymph node and are superior in this respect to 
histopathological examination. Several procedures, such as the RT-LAMP method18, have been 
considered for rapid gene detection. Another such technique is RT-PCR21, although extraction 
and purification of RNA involve time-consuming and difficult steps as well as require trained 
technicians and specifically equipped laboratories. Thus, it is difficult to use RT-PCR as a rapid 
intraoperative test at ordinary testing laboratories.  
For these reasons, there is a need for a new accurate intraoperative test that rapidly detects 
metastasis in a simple manner in sentinel lymph node biopsy. One such candidate is the rapid 
OSNA assay, which is a rapid semi-quantitative assay for intraoperative detection of CK19 
mRNA3. The OSNA assay does not require extraction and preparation of mRNA, and thus the 
entire gene amplification procedure is completed in 30 min, more quickly than for conventional 
PCR. The accuracy of the OSNA assay in breast, gastric, and colorectal cancer has already been 
verified in multicenter clinical trials12-14,22,23. In head and neck squamous cell carcinomas as well, 
the OSNA assay has been reported as a valid method for detecting lymph node metastasis15,16.  
CK19 is a typical epithelial cell marker widely expressed in human cancer, and expression of 
marker was observed in more than 90% of breast cancers24. Increased expression of CK19 
associated with head and neck carcinogenesis and CK19 was expressed in 82% of the specimens 
from head and neck cancer patients25. The CK19 positive rate in cancerous tissue of oral 
squamous cell carcinoma patients was 91% detected using immunohistochemistry26. It is 
considered to be a highly sensitive and useful marker for detecting lymph node metastasis in 
various types of cancer, including head and neck squamous cell carcinoma27,28.  
This protein is expressed in most, but not all, breast cancer cases. Although the OSNA assay has 
proven useful in breast cancer, this prevalent expression of CK19 suggests there is a risk of false 
negatives by the OSNA assay when testing CK19-negative patients that have breast cancer10 and, 
8 
 
similarly, those with head and neck squamous cell carcinoma.  
Sentinel lymph node biopsy detects metastasis in patients even when not clinically evident. 
So that our experimental conditions were as similar to current clinical practice as possible, we 
examined patients with no clinical CLN metastasis by the OSNA assay and histopathology of 
primary lesions and lymph nodes.  This approach tested the accuracy of the OSNA assay in 
head and neck squamous cell carcinoma. Although the two methods detect different events 
(expression of CK19 mRNA by the OSNA assay versus expression of CK19 protein by 
immunohistochemistry), in most cases in this study, the results of the two methods were in good 
agreement, suggesting a strong correlation between CK19 protein expression and the presence 
of CK19 mRNA.  
Immunostaining revealed that less than half (43%) of subjects had a CK19-positive primary 
lesion. A previous study of patients with lingual cancer reported a rate of primary lesions with 
positive immunostaining for CK19 of 47%29, supporting the notion that CK19 is not an 
epithelial cell marker highly expressed in all patients with head and neck squamous cell 
carcinoma. Additionally, we found that lymph nodes positive for CK19 by immunostaining were 
found only when primary lesions were also stained positive for CK19. It is highly likely that 
positive immunostaining for CK19 in lymph nodes is associated with the characteristics of 
primary lesions.  
In patients with a primary lesion CK19-positive by immunostaining, the sensitivity and 
specificity of the OSNA assay against HE staining of the lymph nodes were 86% and 100%, 
respectively. On the other hand, in patients with a primary lesion CK19-negative by 
immunostaining, the sensitivity and specificity of the OSNA assay were 50% and 97%, 
respectively. Thus, the accuracy of the OSNA assay was higher in patients with a CK19- 
positive primary lesion by immunostaining than in those with a CK19-negative primary lesion 
by immunostaining. This finding suggests that positive staining for CK19 in primary lesions is a 
prerequisite for detecting lymph node metastasis by the OSNA assay.  
Among patients with a primary lesion CK19-positive by immunostaining, one lymph node had 
discrepant results for metastasis between HE staining (positive) and the OSNA assay (negative). 
This lymph node immunostaining was also negative for CK19, suggesting possible 
discrepancies in CK19 expression between the primary lesion and lymph nodes. None of the 
patients with a primary lesion CK19 negative by immunostaining had lymph nodes positively 
immunostained for CK19. Expression levels of CK19 mRNA in two lymph node metastases 
(diagnosed by HE staining) were 1.31×102 copies/µl (cut-off value) and 6 copies/µl. This 
indicates that detecting lymph node metastasis by the OSNA assay is highly unlikely when 
primary lesions are negatively stained for CK19. On the other hand, in one lymph node, the 
OSNA result was positive even though metastasis was absent. This may have been due to 
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contamination of epithelial tissue specimens before proceeding with the OSNA assay. 
Contamination can occur during experimental procedures, but CLN specimens themselves have 
been reported to contain thyroid tissue (1.5%)30 and salivary gland tissue (0.9%)31. This 
contamination is a problem not limited to tests for metastasis in the head and neck region and 
needs to be accounted for when testing for metastasis using any epithelial gene. The other 
possible reason being is that approximately half of each CLN was provided for the OSNA assay, 
and the other half was used for histological analysis. There is a possibility that metastatic cells 
were present in only the specimen for OSNA assay. 
This study revealed that CK19 expression is not high in head and neck squamous cell carcinoma, 
suggesting that not all patients can benefit from the OSNA assay for detecting CLN metastasis. 
The study further suggests that the OSNA assay may be valid only in patients with a primary 
lesion positive for CK19 by immunostaining. Although this was an experimental study, our 
findings indicate that to select patients who might benefit from the OSNA assay in the clinical 
setting, it is preferable to examine CK19 expression at the time of preoperative pathological 
diagnosis of the primary lesion. 
In the head and neck squamous cell carcinomas, using the OSNA assay, a detailed relationship 
of the CK19 expression between a primary lesion and lymph nodes was examined. 
These results suggest that the OSNA assay offers similar diagnostic potential to that of the 
histopathological diagnosis of CLN biopsy in patients with a CK19-positive primary lesion. 
It is desirable to actually examine the utility of the OSNA assay for the metastatic diagnosis of  
a sentinel lymph node in the patients with head and neck squamous cell carcinoma in the next 
step study. 
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Figure Legends 
 
Figure 1  Processing for HE staining, CK19 immunostaining, and the OSNA assay in CLN. 
Preparation of lymph nodes for the OSNA assay and histopathological examination. Lymph nodes were 
divided into four pieces (a, b, c, and d), and two pieces (b, d) were homogenized and subjected to the 
OSNA assay. A pair of sections obtained from the cut surface of another two pieces (a, c) was examined 
with HE staining and CK19 immunostaining. 
 
Figure 4   Histopathological and Immunohistological findings in a hypopharynx case. (A) Primary 
lesion of HE staining .Well-differentiated squamous carcinoma (×100). (B) Primary lesion of  
CK19-positive by immunostaining (×100). (C) Metastatic lymph node of HE staining (×40). (D) 
Metastatic lymph node of CK19-positive by immunostaining (×40). 
 
Figure 6   Histopathological and Immunohistological findings in an oral cavity case. (A) Primary lesion 
of HE staining .Well-differentiated squamous carcinoma (×100). (B) Primary lesion of  CK19-negative 
by immunostaining (×100). (C) Non-metastatic lymph node of HE staining (×40). (D) Non-metastatic 
lymph node of CK19-negative by immunostaining (×40). 
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